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ABSTRACT
Mixed chimerism in the T cell compartment (MCT) after reduced-intensity stem cell transplantation (RIST)
may influence immune repopulation with alloreactive donor T cells. We examined effects of host T cell
numbers on donor T cell engraftment and recovery and on acute graft-versus-host disease (aGVHD) in a
relatively homogeneous patient population with respect to residual host T cells through quantified immune
depletion prior to RIST and to donor T cells by setting the allograft T cell dose of 1  105 CD3 cells/kg. In
this setting, 2 patterns of early donor T cell engraftment could be distinguished by day 42: (1) early and
complete donor chimerism in the T cell compartment (FDCT) and (2) persistent MCT. FDCT was associated
with lower residual host CD8 T cell counts prior to transplant and aGVHD. With persistent MCT, subse-
quent development of aGVHD could be predicted by the direction of change in T cell donor chimerism after
donor lymphocyte infusion, and no aGVHD occurred until FDCT was established. MCT did not affect recovery
of donor T cell counts. These observations suggest that the relative number and alloreactivity of donor and
host T cells are more important than the absolute allograft T cell dose in determining donor engraftment and
aGVHD after RIST.
© 2007 American Society for Blood and Marrow Transplantation
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MNTRODUCTION
Reduced-intensity allogeneic hematopoietic stem
ell transplantation (RIST) is increasingly used to de-
rease transplant-related complications and broaden
he pool of patients who could potentially beneﬁt
rom this form of therapy. Reports of outcomes after
IST differ widely in the rate and consistency of
onor engraftment, depending to a large extent on
ost immune status prior to transplantation, the in-
ensity of preparative immune depletion, and the post-
ransplant immune suppression strategy employed
1-7]. A period of mixed donor-recipient chimerism is
requently observed after RIST, with delayed graft-
ersus-tumor (GVT) effects and occasional graft fail- o
022re described [1,8,9]. It has been suggested that full
onor chimerism in the T cell compartment (FDCT)
s a prerequisite for both GVT and graft-versus-host
isease (GVHD), which implies a potential role for
ost T cells in limiting donor T cell alloreactivity
1,10,11]. Attempts have been made to exploit mixed
himerism in the T cell compartment (MCT) as part
f a strategy for attaining immunologic tolerance in
ransplantation for nonmalignant conditions [12,13],
n which alloreactivity plays no therapeutic role. In
ontrast, others have observed both GVT and GVHD
n patients with coincident MCT [2], consistent with
CT reﬂecting bidirectional host-graft reactivity with
ngoing potential for clinical manifestation. The ul-
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T Cell Dose Effects after RIST 1023imate establishment of FDCT or late graft failure
uggests that host-graft interactions may be inherently
nstable, culminating in deletion of either the host or
onor T cell populations. In the treatment of malig-
ant disease, the clinical relevance of MCT remains
ontroversial—not only in its implications for stable
onor engraftment, but also in whether ongoing MCT
lters potential GVT efﬁcacy or risk for GVHD.
We examined clinical manifestations of donor chi-
erism progression in a study of allogeneic RIST for
atients with metastatic breast cancer. Two major
ims of the protocol were to demonstrate donor en-
raftment after RIST with a T cell-depleted (TCD)
llograft and to deﬁne a GVT effect in breast cancer
10]. We adopted an approach of targeted host im-
une depletion prior to RIST with a uniformly TCD
llograft; to potentiate GVT effects, this was followed
y rapid taper of cyclosporine and planned, sequential
onor lymphocyte infusions (DLI). This strategy al-
owed separation of breast cancer responses attribut-
ble to allogeneic cell therapy from those because of
ytotoxic chemotherapy given as part of the prepara-
ive regimen. The intent of allograft TCD with de-
ayed T cell add-back was to permit rigorous evalua-
ion of GVT effects; this is in contrast to other studies
hat employed similar approaches to prevent GVHD
14-16]. Although all patients ultimately completed
onor engraftment, the degree and duration of MCT
as quite variable. Relatively homogeneous popula-
ions with respect to both host and donor T cell
umbers at the time of transplantation provided a
nique opportunity to study dose effects on engraft-
ent. We performed quantitative assessment of cir-
ulating donor and host lymphocyte populations be-
ore and after RIST to assess the relationship between
mmune recovery of host and donor T cells and clin-
cal events after transplant. To differentiate the inﬂu-
nce of host immune depletion from those of allograft
cell depletion and delayed DLI, donor engraftment
nd immune recovery after TCD allografting was
ompared with patients with hematologic malignan-
ies who were treated with unmanipulated allografts
fter a similar approach of host immune depletion
rior to RIST.
ATERIALS AND METHODS
atients and Treatments
Data for this analysis came from patients with
etastatic breast cancer who were enrolled on
ational Cancer Institute (NCI) protocol 00-C-0119,
hich evaluated targeted immune depletion prior to
IST with ex vivo TCD of the allografts followed by
equential DLI. As previously described [10,17], in-
uction consisting of up to 3 cycles of ﬂudarabine and
yclophosphamide was given at conventional doses for ltargeted CD4 T cell depletion to below 50
ells/L. This was followed by reduced intensity con-
itioning (RIC) with ﬂudarabine and cyclophospha-
ide. Sibling donors were an exact HLA match for
LA-A, -B, -Cw, -DRB1, and -DQB1 at the low-
esolution molecular level, and conﬁrmatory types
ere performed providing information for HLA-
RB1 at the high-resolution molecular level. Granu-
ocyte colony-stimulating factor (G-CSF)-mobilized
eripheral blood allografts from donors were ex vivo
cell-depleted with the Isolex 300i immunomagnetic
ell selection system (Nexell Therapeutics, Irvine,
A), using the manufacturer’s antibody for positive
election of CD34 cells and a combination of three T
ell-speciﬁc monoclonal antibodies (CD2, CD6, and
D7) for negative selection of T cells (“positive-neg-
tive selection”), resulting in a consistent 4 to 5-log
epletion of T cells. Unmanipulated lymphocytes
ere added back so that allografts contained a ﬁnal T
ell dose of 1  105CD3cells/kg. Patients received
VHD prophylaxis with cyclosporine through day
28 and rapidly tapered off by day 42 to potentiate
VT effects against the breast cancer. Scheduled DLI
ere administered to all patients without evidence of
VHD (irrespective of donor chimerism) on days 42,
0, and 98 posttransplant (1  106, 5  106, and 1 
07 CD3 cells/kg, respectively). Patients could re-
eive additional DLI beyond day 98 if clinically
ndicated.
Comparison was made with patients with hema-
ologic malignancies treated with unmanipulated allo-
rafts (also from HLA-identical siblings with typing
erformed as above) using a similar preparative ap-
roach (NCI 99-C-0143), except the induction regi-
en used for targeted immune depletion was
POCH-F (ﬂudarabine, etoposide, doxorubicin, vin-
ristine, cyclophosphamide, and prednisone) [18,19].
he conditioning regimen was identical to 00-C-
119. GVHD prophylaxis also consisted of single-
gent cyclosporine, although it was continued through
ay 180. The expected differences in diagnoses and
rior therapies on patient immune status at the time of
nrollment in the 2 protocols were minimized by
dministration of induction with similarly immune-
epleting regimens and application of identical crite-
ia (CD4 T cell count 50 cells/L, Grade 4 neu-
ropenia or disease progression) for proceeding to the
onditioning regimen and allografting.
ymphocyte Population Identification
nd Quantification
The absolute numbers of circulating host CD3
cells, CD4 and CD8 T cells, natural killer cells,
nd B cells were determined at study entry, postin-
uction, and at days 0, 28, and 98 posttransplant.
low cytometry was performed in a CLIA-certiﬁed
aboratory (Science Applications International Corpo-
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N. M. Hardy et al.1024ation; Frederick, MD). Complete blood counts and
ifferentials, performed in the NIH Clinical Center
aboratory, were then used to calculate the absolute
umber of CD3, CD4, and CD8 T cells (and
ubsets), natural killer cells, and B cells per microliter
L) of blood from the percentage of the CD45
opulation. In the case of T cells, estimation of num-
ers of circulating cells of donor and host origin were
erived from calculated absolute T cell counts and
easurements of donor chimerism within CD3
ells obtained from the same blood draws (described
elow). T cells and their subsets were deﬁned as
ollows: T cells were CD3; CD4 T cells were
D3CD4; CD8T cells were CD3CD8, B cells
ere CD19CD3; and natural killer cells were
D3CD56CD16/.
ssessment of Chimerism
Chimerism analysis was performed by PCR-based
omparison of variable number tandem repeats in a
LIA-certiﬁed laboratory at the Blood Center of
outheastern Wisconsin (Milwaukee, WI) [20]. Chi-
erism determinations on samples enriched for T
ells (CD3) were made every 14 days through day
98, and monthly thereafter. T cell enrichment to
95% purity was performed either by positive selection
sing magnetic beads, (Miltenyi, Inc., Auburn, CA) or
osette technique (Stem Cell Technologies, Inc., Van-
ouver, BC). Establishment of FDCT was deﬁned as the
rst time point after which the donor fraction of CD3-
nriched cells was consistently 90%.
tatistical Analysis
Comparisons within the TCD recipients were
ade with respect to a speciﬁed set of dichotomous
arameters: patients with rapid vs. delayed engraft-
ent (stable full-donor T cell engraftment (chimerism
90%) by day 42 vs. mixed T cell chimerism at day
2; patients who demonstrated complete donor T cell
ngraftment by day 70 versus those who did not (com-
lete donor T cell engraftment deﬁned as stable donor
D3 cell chimerism greater than 90% at day 70);
atients who developed signiﬁcant acute GVHD
aGVHD) versus those who did not (signiﬁcant
GVHD deﬁned here, using the Glucksberg Criteria,
s a maximum grade of II to IV and including “late”
GVHD, occuring after day 100 following receipt of
LI). In each of these analyses, as well as comparisons
f absolute numbers of lymphocyte populations be-
ween TCD and TCR recipients, the comparison was
erformed using an exact Wilcoxon rank-sum test. As
very large number of exploratory analyses were per-
ormed, with varying degrees of independence and
ependence of the parameters being compared, only
-values .005 have been interpreted as indicating a
tatistically signiﬁcant difference or trend P-values f.005 but .05 were interpreted as trends toward
tatistical signiﬁcance. All P-values presented are 2
ailed and without any adjustment for multiple com-
arisons.
ESULTS
atient Characteristics and Transplant Outcomes
Characteristics of patients, donors, and clinical
utcomes are summarized in Tables 1 and 2. Nineteen
atients received allografts on the TCD study and 20
atients received allografts on the TCR study. Pa-
ients enrolled in the 2 protocols were similar in age,
MV status, donor characteristics, and CD34 cell
ose received. Median survival at days 28 and
100 was similar between the 2 groups. Overall
urvival (OS) rates were markedly lower among
CD recipients largely reﬂecting higher rates of
elapse in this patient population with advanced
etastatic breast cancer.
Targeted host immune depletion achieved similar
eduction of circulating lymphocyte counts in the
CD and TCR protocols, except CD4 T cells,
hich were somewhat lower among TCD recipients
44 versus 71 cells/mL, P  .017). At day 0, prior to
llograft infusion, T cell counts were uniformly 50
ells/L in both groups. The overall incidence of
rade II-IV aGVHD was not statistically different
etween the two groups (71% versus 70% for TCD
ersus TCR, P  1.00). Survival between the two
roups at days 28 and 100 was also similar. Con-
istent with the prognoses of the underlying malig-
ancies in the 2 studies, overall median survival was
igniﬁcantly different between the 2 groups.
elayed T Cell Engraftment following TCD RIST
Although no graft failure was observed on either
rotocol, establishment of stable FDCT was signiﬁ-
antly delayed in the recipients of TCD allografts
ompared to TCR (median 70 days versus 14 days,
espectively, P .0044, Figure 1). The period of MCT
ollowing TCD allografting permitted evaluation of
onor T cell engraftment kinetics and host T cell
ecovery that could not be performed in the TCR
ecipients because of their rapid establishment of
DCT. Following TCD, 2 patterns of T cell engraft-
ent were observed: some patients demonstrated
apid establishment of stable FDCT prior to scheduled
LI on day 42 (8 patients, median day 21), and
thers demonstrated persistent MCT until after 1 or
ore DLI (10 patients, median day126; Table 2 and
igure 2). One patient with rapid engraftment died of
nfection at day 26 and was omitted from these
nalyses. One patient with MCT died of progressive
isease after the ﬁrst DLI, prior to demonstration of
ull engraftment.
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T Cell Dose Effects after RIST 1025ixed Chimerism of the T Cell Compartment
Progression of donor chimerism of the T cell
ompartment among the MCT subset of TCD re-
ipients was variable and often uneven (Figure 2):
onor chimerism decreased between days 14 and
28 in 6 of 7 evaluable patients; upon completion
f cyclosporine taper in 3 of 9 patients; and after the
rst DLI in 4 of 8 evaluable patients. T cell chi-
erism fell after the ﬁrst DLI in all patients who
id not ultimately develop aGVHD, regardless of
onor or host predominance at day 42. All of
hose in whom T cell chimerism was stable or in-
reased after the ﬁrst DLI eventually developed
GVHD. Rapid and consistent progression in donor
himerism characterized T cell engraftment of the
ubset with early FDCT, in which all patients de-
eloped aGVHD.
GVHD
The speciﬁc intent of TCD was not GVHD pre-
ention, and we observed nearly identical overall in-
idences of aGVHD after TCD and TCR allograft-
ng. The onset occurred somewhat later after TCD
han TCR (median onset after TCD: 47 days, range:
3-180 days; after TCR: 23 days, range: 11-84 days).
able 1. Patient and Transplant Characteristics and Outcomes
Protocol Parameter
atient/donor characteristics Number and indication
Median recipient age (rang
Median donor age (range)
Donor sex
Female donor/male recipie
CMV risk
ransplant characteristics Induction regimen
Median number of inductio
cycles
ostinduction cell counts, cells/L CD3
CD4, P  .017
CD8
NK
ay 0 host cell counts, cells/L
allograft composition CD3
Median CD34 cells/kg
Median CD3 cells/kg
ransplant outcomes
hematopoietic recovery
Neutrophils >1000 cells/L
Platelets >100,000/L
onor T cell engraftment Stable FDCT
Day 28 FDCT, P  .0044
Day 100 FDCT, P  .023
linical events Grade II-IV aGVHD
number/evaluable (%),
P  1.00
Median survival (day 28/
day 100)
GVHD indicates acute graft-versus-host disease; M  male; F mong TCD recipients, all 7 evaluable patients who established FDCT prior to DLI developed signiﬁcant
grade II-IV) aGVHD, compared to 4 of the 10 pa-
ients with initial MCT (P  .035). Notably, none of
he patients developed aGVHD prior to the establish-
ent of FDCT (Figure 3). Clinical aGVHD often
losely followed T cell engraftment, and all in the
apid engraftment group developed aGVHD at or
oon after the completion of FDCT.
Scheduled DLI were not administered to patients
ith active aGVHD, and so the total T cell dose did
ot correlate with the development of aGVHD (Fig-
re 3). Three patients developed aGVHD precluding
dministration of any DLI; 5 patients developed
GVHD after the ﬁrst DLI (with 1  106 T cells/kg)
nd 2 patients after the second DLI (total of 6  106
cells/kg). Only 2 of the 7 patients who received all
of the scheduled DLI (total of 1.6  107 T cells/kg)
eveloped signiﬁcant aGVHD.
ost T Cell Dose Effects
Administration of uniformly reduced allograft T
ell doses after ex vivo TCD permitted evaluation of
ost T cell dose effects on donor T cell engraftment.
uantiﬁcation of peripheral blood lymphocyte subsets
t day 21 of the ﬁnal cycle of induction was used to
00-C-0119: TCD Median
(Range)
99-C-0143: TCR Median
(Range)
9 (metastatic breast cancer) 20 (relapsed or refractory
hematologic malignancy)
3 years (32-56) 44 (19-67)
4 years (30-65) 43 (16-74)
: 12 (63%); F: 7 (37%) M: 11 (55%); F: 9 (45%)
0 7 (35%)
4/19 16/20
lu/Cy EPOCH-F
1 (1-2) 3 (1-3)
86 (1-701) 140 (21-441)
44 (1-156) 71 (12-191)
34 (0-555) 55 (2-309)
58 (0-376) 88 (3-467)
1 (1-6) 5 (0-42)
.75  106 (5.1-12.9) 7.68  106 (4.6-18.4)
.0  105 (preset) 3.63  108 (1.5-8.3)
ay 9 (8-11)
ay 17 (11-40)
Day 9 (7-12)
Day 16 (12-42)
ay 70 (14-180) Day 14 (14-100)
7/15 (47%) (25-100%) 17/18 (94%) (85-100%)
9/13 (69%) (35-100%) 18/18 (100%)
2/17 (71%) (13/20 by day 100) 14/20 (70%) (all by day 100)
25 days (89%/79%) 1154 days (100%/90%)
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N. M. Hardy et al.1026itioning for transplantation. The median circulating
esidual host T cell count was signiﬁcantly lower in
he early FDCT group than in the group with MCT
able 2. TCD Patient Clinical Outcomes
UPN*
Postinduction Host
CD8 T Cell
Count FDCT (Day)
# DLI Prior to
Day 100
24 0 28 1
12 10 126 2
16 15 14 1
18 18 21 1
6 18 42 0
10 23 14 0
17 26 14 1
4† 32 n/a n/a
11 32 126 2
20 34 180 2
1 47 98 2
22 53 21 0
23† 58 28 n/a
9 154 >98§ 2
3 154 84 2
5 206 >42 1
7 296 126 2
2 335 126 2
25 555 70 1
GVHD indicates acute graft-versus-host disease; DLI, donor leuk
Unique patient number.
*Glucksberg Criteria [21].
Excluded from analyses because of death prior to day 28.
100% donor in peripheral whole blood.
§Late-aGVHD after 4th DLI.
igure 1. The magnitude and duration of mixed chimerism in the
cell compartment is variable after TID-RIST with TCD.
, Peripheral blood T cell donor chimerism after TCD (top) and
CR (bottom) RIST. B, Two patterns of donor T cell engraftment
re seen after TCD-RIST. (Top) Rapid engraftment was charac-
erized by stable complete donor T cell chimerism by day 42,
rior to DLI. (Bottom) MCT was characterized by variable donor
bimerism in the T cell compartment, and FDCT established after
dministration of DLI. Black bars: median values; shaded bars: ﬁrst
nd third quartiles; lines: ranges. a47 versus 229 cells/L, P  .0097). The median
D8 T cell count was lower as well (18 versus 154
ells/L, P  .0089, Figure 4), whereas CD4 T cell
ounts and natural killer cell counts were not sig-
iﬁcantly different between the two groups. Al-
hough associated with delayed establishment of
DCT, high residual host CD8
 T cell counts did not
ecessarily protect against the ultimate development
rior to
CT
Maximum Grade
aGVHD Skin/
Gut/Liver**
Day of Onset aGVHD
(Grade I)
Survival
(Days)
0 3/2/0 47 172
3 0/0/0 n/a 562
0 3/1/1 66 148
0 2/0/0 32 161
0 3/1/0 38 278
0 2/1/2 23 76
0 1/2/0 46 503
/a n/a n/a 2
3 0/0/0 (139) 895
4 0/0/0 n/a 225
2 2/3/4 103 (40) 172
0 3/1/0 42 125
0 n/a n/a 26
2 0/2/0 90 421
2 0/0/0 n/a 541
1 0/0/0 n/a 76
3 2/3/2 180§§ 352
3 1/1/0 (54) >1936
1 3/1/0 71 290
nfusions; n/a, not applicable; TCD, T cell depleted.
igure 2. Progression toward FDCT is uneven after TCD RIST.
ines connect T cell chimerism data points for individual subjects
ith MCT; shaded area: donor chimerism 90%; solid lines: patients
ith less than grade II aGVHD; dotted lines: patients who devel-
ped grades II-IV acute GVHD; open triangle: cyclosporine taper;# DLI P
FD
n
ocyte irrows: scheduled DLI.
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T Cell Dose Effects after RIST 1027f signiﬁcant aGVHD. Although the number of sub-
ects is small, differences in residual host CD8 T cell
ounts among those who did and did not develop
GVHD were not statistically signiﬁcant (29 versus
54 cells/L; P  .40, Figure 4), with extensive over-
ap between the distributions.
Donor chimerism in the T cell compartment re-
ects relative rates of recovery of host and donor T
ell numbers—the net result of proliferation and loss
22]. Compared to TCR recipients, day 28 recovery
f total numbers of T cells after TCD was not im-
aired (246 versus 153 T cells/L, P .14). However,
cell chimerism analysis revealed that the number of
irculating T cells of donor origin was lower following
CD (100 versus 246/L, P .023). The discrepancy
etween total and donor T cell counts reﬂects the
requent persistence of circulating host T cells after
CD allografting that was not evident after TCR
igure 3. aGVHD was observed at or after establishment of FDCT
egardless of DLI administration. A, All 7 of the patients in the
apid engraftment subgroup developed aGVHD, including 3 prior
o receiving any scheduled DLI. aGVHD occurred in 4 of 10
atients with MCT. The shaded triangle, below the line connecting
ymmetrical time points, represents the theoretical area in which
alues would fall if subjects developed aGVHD at or before the
stablishment of FDCT. Arrows: scheduled DLI. B, Incidence and
nset of aGVHD after TCD according to number of scheduled
LI received.rafts. By day 100, total numbers remained similar, pnd the effect of allograft TCD on donor T cell
ounts was no longer apparent (481 versus 471 donor
cells/L, P  .36).
To examine whether MCT among TCD recipi-
nts reﬂected host T cell expansion or compromised
onor T cell recovery, we compared peripheral T cell
ounts among the groups with rapid and MCT pat-
erns of donor T cell engraftment. At days 28 and
100, neither total nor donor T cell counts were
igniﬁcantly different among those with rapid engraft-
ent compared to those with MCT. In contrast, host
cell counts were higher in those with MCT at both
ime points, reaching signiﬁcance at day 28 (day
28: 1 versus 66 cells/L, P  .00067; day 100: 0
ersus 21 cells/L, P  .033, Figure 5). Next we
valuated whether clinical evidence of donor-medi-
ted alloreactivity in the form of aGVHD inﬂuenced
eripheral T cell counts. As noted above, aGVHD did
ot occur in the setting of MCT: thus, the develop-
ent of aGVHD followed the elimination of host T
ells. Although no differences could be detected in
otal or donor T cell counts at day 28, donor T cell
ounts at day 100 were higher in TCD recipients
ho developed grade II-IV aGVHD than in those
ho did not (579 versus 184 cells/L, P  .045).
VT Effects
As has previously been reported [10], immune-me-
iated GVT responses were demonstrated in 32% of
CD recipients, and 25% had some disease stabiliza-
ion, which was also likely mediated by GVT in this
reatment-refractory group of patients. Although all tu-
or responses were seen at or after the time of FDCT,
o differences in rates of engraftment, aGVHD, or im-
une recovery were found comparing those with and
ithout evidence of a GVT effect (data not shown).
igure 4. Although host CD8 T cell counts were associated with
CT there was no direct association with aGVHD. Postinduction
irculating CD8 T cell counts in TCD recipients with MCT and
apid FDCT (left panel) and grade 0-I versus II-IV aGVHD (right
anel). Bars: median values.
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N. M. Hardy et al.1028ISCUSSION
Host immune depletion with a deﬁned CD4 T
ell-count target plus ex vivo allograft TCD with
elatively uniform donor T cell dose provided a
nique opportunity to investigate donor and host T
ell dose effects on donor T cell engraftment and
ecovery and the development of aGVHD after RIST.
ollowing administration of TCD allografts, we ob-
erved delayed donor T cell engraftment and recovery,
vidence of host CD8 T cell dose effect on the kinetics
f donor T cell engraftment, and a relatively high inci-
ence of aGVHD upon establishment of FDCT.
As has been reported after myeloablative HSCT
23], ex vivo TCD results in delayed donor T cell
ngraftment after RIST. In contrast to the myeloab-
ative setting, however, even after rigorous immune
epletion prior to conditioning, persistence of host T
ells contributed to T cell recovery early after RIST
ith TCD such that total numbers of circulating T
ells were not different than those observed after TCR
llografting. We did not observe signiﬁcant recovery
f circulating host T cell counts after TCR allograft-
ng, although comparable levels of host immune de-
letion were achieved. This suggests that the relative
roportion of donor to residual host T cell numbers at
he time of transplantation is an important determi-
ant of early recovery of both donor and host T cell
ounts, and demonstrates the clinical importance of
onor cell-mediated deletion of residual host T cells
n the establishment of FDCT. This extends the ob-
ervations made by several authors [1,2,24] that the
ntensity of cytotoxic therapy received prior to RIST
ccounts for variable kinetics of T cell engraftment by
eﬁning a role for host T cell persistence.
Following RIST with TCD, quantiﬁcation of cir-
igure 5. Patterns of T cell recovery after TCD. A, Recovery of cir
ut not donor T cell counts are affected by engraftment kinetics. B
GVHD suggest greater donor T cell expansion in those who develo
nd lines: range.ulating host T cells, prior to conditioning permitted rstandardized evaluation of their effects on donor T
ell engraftment and aGVHD. Two patterns of donor
cell engraftment were observed after TCD, based
n donor chimerism prior to DLI administration.
apid establishment of FDCT prior to DLI was asso-
iated with both lower residual host CD8 T cell
ounts and development of aGVHD. Residual host
D8 T cell counts alone did not predict aGVHD in
ll patients, as a minority of patients with MCT had
ery high residual host CD8T cell counts, consistent
rogression toward FDCT with administration of
LI, and ultimately developed aGVHD. In the pa-
ients with MCT who did not develop aGVHD, loss of
onor chimerism in response to the ﬁrst DLI, which
as not predicted by residual host CD8 T cell
ounts, is likely a clinical manifestation of host-versus-
raft reactivity. Although the numbers are small, these
bservations highlight the importance of the intensity
f host-graft reactivity separate from donor and host
ell dose effects on clinical transplant outcomes.
The similar incidences of aGVHD observed after
IST with TCD and TCR allografts are explained in
art by the early, rapid cyclosporine taper and admin-
stration of DLI after TCD allografting. In our TCD
ecipients, aGVHD and, as previously reported [10],
VT effect were not seen until at or after the time
DCT was established. Development of aGVHD and
VT effect in the setting of MCT have been reported
fter truly nonmyeloablative HSCT whereas others
ave reported similar dependence upon FDCT using
IC regimens [1,25]. Two factors that may contribute
o the apparent protective effect of MCT include (1) a
ost T cell-mediated “veto-like” deletion of alloreac-
ive donor T cells; and (2) the effect of competition,
ith kinetics of donor T cell expansion and antihost
T cells in TCD recipients with MCT and rapid FDCT shows host
versus donor T cell recovery in those with grade 0-I versus II-IV
D. Black bars: median values; shaded bars: ﬁrst and third quartiles,culating
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T Cell Dose Effects after RIST 1029ver donor T cell populations that are reactive to
ther host tissues. The decrease in chimerism after
LI observed in the TCD recipients that did not
evelop aGVHD may reﬂect expansion of alloreactive
ost cells in response to a booster effect of the addi-
ional donor cells and/or host-mediated deletion of
lloreactive donor cells; the latter would suggest that
ost cells play an active role in controlling GVHD
and potentially abrogating the GVT effect) in the
etting of MCT. Our observation that circulating do-
or T cell counts were not affected by MCT could
uggest an absence of such host cell-mediated donor T
ell interference. No conclusion can be drawn, how-
ver, as circulating counts are not likely to be an
ccurate reﬂection of cell populations in the tissues.
y day 100, donor T cells were signiﬁcantly higher
n the subset of TCD recipients who developed
GVHD, perhaps reﬂecting antigen-driven peripheral
xpansion [26,27] of host-reactive T cell clones that
ere not deleted in this group of patients.
On the other hand, reports of aGVHD in the
etting of MCT following nonmyeloablative HSCT
2] suggest that host cell persistence is insufﬁcient to
rotect against clinical aGVHD, and perhaps when
elative and absolute donor and host cell doses allow
rolonged host-graft competition for engraftment,
lones with speciﬁcity for less immunogenic GVH
arget tissues may outpace antihematopoietic counter-
arts, accounting for clinical GVHD and GVT effects
ppearing prior to FDCT. Factors that modulate host
issue immunogenicity may further explain the appear-
nce of clinical GVHD prior to elimination of host T
ells. For example, truly nonmyeloablative regimensmay
ave greater tissue sparing of host antigen-presenting
ells, which are key in the pathobiology of aGVHD [28],
nd may well play a role in GVT as well [29], and
otal-body irradiation may promote GVHD through
idespread, subclinical tissue injury.
Together, these observations suggest the impor-
ance of the relative numbers of donor and host T cells
ver the absolute donor T cell dose in determining the
inetics of engraftment and the development of
GVHD. Severely immune-depleted patients under-
oing RIST, including patients who have been heavily
retreated with cytotoxic therapies, may have a lower
llograft T cell dose requirement, and beneﬁt from a
ower T cell dose. Further, both rapid establishment
f FDCT and, in those with MCT, advancing donor
himerism following low-dose DLI appear to predict
he risk of aGVHD. These patterns of engraftment
inetics may prospectively identify patients who need
ontinued prophylactic immune suppression or in
hom to avoid full-dose DLI. Conversely, a decline in
onor chimerism following DLI in patients with MCT
ay herald graft failure and identify a group of pa-ients for whom additionally, higher doses of DLI maye both beneﬁcial and relatively safe. The role of host
ells in determining clinical outcomes such as GVT
esponses, GVHD and immune reconstitution remain
mportant issues for further research.
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